NIVOLUMAB WITH AZACYTIDINE IN PEDIATRIC RELAPSED/REFRACTORY AML:PHASE I RESULTS FROM TACL CONSORTIUM

被引：0
|
作者：
Verma, Anupam [1 ]
Chi, Yueh-Yun [1 ]
Malvar, Jemily [1 ]
Lamble, Adam [1 ]
Chaudhury, Sonali [1 ]
Sung, Lillian [1 ]
Agarwal, Archana [1 ]
Liang, Gangning [1 ]
Sposto, Richard [1 ]
Leong, Roy [1 ]
Brown, Patrick [1 ]
Kaplan, Joel [1 ]
Schafer, Eric [1 ]
Slone, Tamra [1 ]
Pauly, Melinda [1 ]
Chang, Bill [1 ]
Stieglitz, Elliot [1 ]
Wayne, Alan [1 ]
Hijiya, Nobuko [1 ]
Bhoywani, Deepa [1 ]
机构：
[1] Therapeut Adv Childhood Leukemia & Lymphoma, Salt Lake City, UT USA
来源：
PEDIATRIC BLOOD & CANCER | 2022年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
213
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Lintuzumab-225Ac in Combination with Venetoclax in Relapsed/Refractory AML: Early Results of a Phase I/II Study
    Hegazi, Mohamed M.
    Harpel, John G.
    Miao, Sara
    Ludwig, Dale
    Berger, Mark S.
    Schiller, Gary J.
    BLOOD, 2020, 136
  • [22] PHASE IB/II STUDY OF NIVOLUMAB IN COMBINATION WITH 5-AZACYTIDINE (AZA) IN PATIENTS (PTS) WITH RELAPSED ACUTE MYELOID LEUKEMIA (AML)
    Daver, N.
    Cortes, J.
    Ravandi, F.
    Basu, S.
    Garcia-Manero, G.
    Jabbour, E.
    Pemmaraju, N.
    Hendrickson, S.
    Pierce, S.
    Ning, J.
    Gonzales, G.
    Konopleva, M.
    Andreeff, M.
    Borthakur, G.
    Bueso-Ramos, C.
    Blando, J.
    Allison, J.
    Kantarjian, H.
    Sharma, P.
    HAEMATOLOGICA, 2016, 101 : 42 - 43
  • [23] DASATINIB IN CHILDREN AND ADOLESCENTS WITH RELAPSED OR REFRACTORY LEUKEMIA: PRELIMINARY RESULTS OF THE CA180018 PHASE I/II STUDY FROM THE ITCC CONSORTIUM
    Zwaan, C. M.
    Keams, P.
    Den Boerd, M. L.
    Beverloo, H. B.
    Van der Velden, V. H. J.
    Van Tornout, J. M. A.
    Derreumaux, D.
    Lehmbecher, T.
    Mechinaud, E.
    Rizzari, C.
    Baruchel, A.
    Pieters, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 367 - 368
  • [24] Dasatinib in Children and Adolescents with Relapsed or Refractory Leukemia: Interim Results of the CA180-018 Phase I Study from the ITCC Consortium
    Zwaan, C. Michel
    Rizzari, Carmelo
    Van der Velden, Vincent H. J.
    Beverloo, Berna
    den Boer, M. L.
    Baruchel, Andre
    Mechinaud, Francoise
    Lancaster, Donna
    Matloub, Yousif
    Derreumaux, Dominique
    Pieters, Rob
    Kearns, Pamela
    BLOOD, 2008, 112 (11) : 1113 - 1113
  • [25] A Phase I Study of AC220 in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
    Cooper, Todd
    Sposto, Richard
    Cassar, Jeannette
    Eckroth, Elena
    Malvar, Jemily
    Gaynon, Paul
    Dubois, Steven
    Chang, Bill H.
    Gore, Lia
    August, Keith J.
    Thomson, Blythe
    Gammon, Guy
    Magoon, Daniel
    Annesley, Colleen E.
    Brown, Patrick
    BLOOD, 2012, 120 (21)
  • [26] Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine in Pediatric Patients with Relapsed or Refractory AML
    Rubnitz, Jeffrey E.
    Kaufman, Ronda
    Ribeiro, Raul C.
    Klebanov, Boris
    Ellis, Joel
    Landesman, Yosef
    Youssoufian, Hagop
    Rashal, Tami
    Shacham, Sharon
    BLOOD, 2015, 126 (23)
  • [27] ADVL1412: Initial results of a phase I/II study of nivolumab and ipilimumab in pediatric patients with relapsed/refractory solid tumors-A COG study.
    Davis, Kara L.
    Fox, Elizabeth
    Reid, Joel M.
    Liu, Xiaowei
    Minard, Charles G.
    Weigel, Brenda
    Mackall, Crystal
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML.
    Daver, Naval Guastad
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    Basu, Sreyashi
    Ravandi, Farhad
    Kadia, Tapan M.
    Borthakur, Gautam
    Jabbour, Elias
    Dinardo, Courtney Denton
    Pemmaraju, Naveen
    Brandt, Mark
    Pierce, Sherry
    Hussin, Nawar
    Kornblau, Steven Mitchell
    Andreeff, Michael
    Konopleva, Marina
    Ning, Jing
    Allison, James Patrick
    Sharma, Padmanee
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Phase I Hypofractionation Trial of Relapsed/Refractory Lymphoma: Preliminary Results
    Rajeev-Kumar, G.
    McKeever, M. R.
    Koshy, M.
    McCall, A. R.
    Arif, F.
    Smith, S. M.
    Kline, J.
    Riedell, P.
    Hasans, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : S67 - S68
  • [30] Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
    Kaufman, Jonathan L.
    Mina, Roberto
    Jakubowiak, Andrzej J.
    Zimmermann, Todd L.
    Wolf, Jeffrey J.
    Lewis, Colleen
    Gleason, Charise
    Sharp, Cathy
    Martin, Thomas
    Heffner, Leonard T.
    Nooka, Ajay K.
    Harvey, R. Donald
    Lonial, Sagar
    BLOOD CANCER JOURNAL, 2019, 9 (1)
12345